Sezer, Orhan : Angiogenese und Knochenstoffwechsel beim multiplen Myelom

100

Literaturverzeichnis

1 Abildgaard N, Bentzen SM, Nielsen JL, Heickendorff L. "Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG). " Br J Haematol 1997; 96: 103-110.

2 Abildgaard N, Glerup H, Rungby J, Bendix-Hansen K, Kassem M, Brixen K, Heickendorff L, Nielsen JL, Eriksen EF. "Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. " Eur J Haematol 2000; 64: 121-129.

3 Acenero MJ, Gonzales JF, Gallego GM, Ballesteros PA. "Vascular enumeration as a significant prognosticator for invasive breast carcinoma. " J Clin Oncol 1998; 16: 1684-1688.

4 Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, Giles F, Estrov Z, Barlogie B, Albitar M. "Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. " Blood 1999; 94: 3717-3721.

5 Aguayo A, Kantarjian H, Manshouri T, Gidel C, Thomas D, Koller C, Estrov Z, O‘Brien S, Keating M, Freireich E, Albitar M. "Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. " Blood 2000a; 96: 2240-2245.

6 Aguayo A, O'Brien S, Keating M, Manshouri T, Gidel C, Barlogie B, Beran M, Koller C, Kantarjian H, Albitar M. "Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. " Blood 2000b; 96: 768-770.

7 Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ, Stuckey WJ Jr, Wilson HE. "Treatment of multiple myeloma: combination chemotherapy with different melphalan dose regiments. " JAMA 1969; 208: 1680-1685.

8 Alexanian R, Dimopoulos M. "The treatment of multiple myeloma. " N Engl J Med 1994; 330: 484-489.

9 Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. "In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. " Leukemia 1998; 12: 220-229.

10 Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. "A prospective, randomized "


101

"trial of autologous bone marrow transplantation and chemotherapy in multiple
myeloma. " N Engl J Med 1996; 335: 91-97.

11 Baird A, Böhlen P. "Fibroblast growth factors. " In: Sporn MB, Roberts AB (eds). Peptide growth factors and their receptors I. Springer, Berlin-Heidelberg-New York , 1990 : 369-418.

12 Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, Selby PJ. "Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. " Br J Cancer 1998; 77: 956-964.

13 Barlogie B, Smith L, Alexanian R. "Effective treatment of advanced multiple myeloma refractory to alkylating agents. " N Engl J Med 1984; 310: 1353-1356.

14 Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J. "Total therapy with tandem transplants for newly diagnosed multiple myeloma. " Blood 1999; 93: 55-65.

15 Bataille R, Chappard D, Marcelli C, Rossi JF, Dessauw P, Baldet P, Sany J, Alexandre C. "Osteoblast stimulation in multiple myeloma lacking lytic bone lesions. " Br J Haematol 1990; 76: 484-487.

16 Bataille R, Chappard D, Marcelli C, Dessauw P, Baldet P, Sany J, Alexandre C. "The recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. " J Clin Invest 1991; 88: 62-66.

17 Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. "C-reactive protein and beta2 microglobulin produce a simple and powerful myeloma staging system. " Blood 1992; 80: 733-737.

18 Bataille R. "Mechanisms of bone lesions in multiple myeloma. " Hematol Oncol Clin North Am 1995; 9: 285-295.

19 Bataille R, Chappard D, Basle M. "Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: A prospective study of 87 bone biopsies. " Blood 1996; 11: 4762-4769.

20 Bataille R, Manolagas S, Berenson J. "Pathogenesis and management of bone lesions in multiple myeloma. " Hematol Oncol Clin North Am 1997; 11: 349-361.


102

21 Battegay EJ. "Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. " J Mol Med 1995; 73: 333-346.

22 Bellamy WT, Richter L, Frutiger Y, Grogan TM. "Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. " Cancer Res 1999; 59: 728-733.

23 Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD. "Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. " N Engl J Med 1996; 334: 488-493.

24 Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD. "Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. " J Clin Oncol 1998; 16: 593-600.

25 Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci PF, Cocorocchio E, Goldhirsch A, Martinelli G. "Angiogenic growth factors and endostatin in non-Hodgkin‘s lymphoma. " Br J Haematol 1999; 106: 504-509.

26 Bettica P, Moro L, Robins SP, Taylor AK, Talbot J, Singer FR, Baylink DJ. "Bone-resorption markers galactosyl hydroxylysine, pyridinium crosslinks, and hydroxyproline compared. " Clinical Chemistry 1992; 38: 2313-2318.

27 Beyer J, Schwella N, Zingsem J, Strohscheer I, Schwaner I, Oettle H, Serke S, Huhn D, Siegert W. "Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. " J Clin Oncol 1995; 13: 1328-1335.

28 Bilgrami S, Aslanzadeh J, Feingold JM, Bona RD, Clive J, Dorsky D, Edwards RL, Tutschka PJ. "Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance. " Bone Marrow Transplant 1999; 24: 69-73.

29 Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. "Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. " Br J Haematol 1998; 102: 1115-1123.


103

30 Borset M, Lien E, Espevik T, Helseth E, Waage A, Sundan A. "Concomitant expression of hepatocyte growth factor and the receptor c-Met in human myeloma cell lines. " J Biol Chem 1996; 271: 24655-24661.

31 Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA. "Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. " Science 1991; 251: 802-804.

32 Brattstrom D, Bergqvist M, Larsson A, Holmertz J, Hesselius P, Rosenberg L, Brodin O, Wagenius G. "Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. " Anticancer Res 1998; 18: 1123-1127.

33 Brindle NP. "Growth factors in endothelial regeneration. " Cardiovasc Res 1993; 27: 1162-1172.

34 Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Oliviero M, Naldini L, Gaudino G, Tamagnone L, Coffer A. "Comoglio PM. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. " J Cell Biol 1992; 119: 629-641.

35 Carlson K, Ljunghall S, Simonsson B, Smedmyr B. "Serum osteocalcin concentrations in patients with multiple myeloma - correlation with disease stage and survival. " J Intern Med 1992; 231: 133-137.

36 Chang E, Boyd A, Nelson CC, Crowley D, Law T, Keough KM, Folkman J, Ezekowitz RA, Castle VP. "Successful treatment of infantile hemangiomas with interferon-alpha-2b. " J Pediatr Hematol Oncol 1997; 19: 237-244.

37 Chaudhary R, Bromley M, Clarke NW, Betts CD, Barnard RJ, Ryder WD, Kumar S. "Prognostic relevance of micro-vessel density in cancer of the urinary bladder. " Anticancer Res 1999; 19: 3479-3484.

38 Chronic Leukemia and Myeloma Task Force of the National Cancer Institute: Proposed guidelines for protocol studies. II. Plasma cell myeloma. "Cancer Chemother Rep " 1973; 4: 145-158.

39 Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, Dember LM, Berk JL, Akpek G, LaValley M, O'hara C, Arkin CF, Wright DG, Skinner M. "Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: Survival and responses in 25 patients. " Blood 1998; 91: 3662-3670.

40 Craft PS, Harris AL. "Clinical prognostic significance of tumour angiogenesis. " Ann Oncol 1994; 5: 305-311.


104

41 D‘Amato RJ, Loughnan MS, Flynn E, Folkman J. "Thalidomide is an inhibitor of angiogenesis. " Proc Natl Acad Sci USA 1994; 91: 4082-4085.

42 Dankbar B, Padró T, Leo R, Feldmann B, Kropff M, Mesters RM, Serve H, Berdel WE, Kienast J. "Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. " Blood 2000; 95: 2630-2636.

43 Deplanque G, Harris AL. "Antiangiogenic agents: clinical trial design and therapies in development. " Eur J Cancer 2000; 36: 1713-1724.

44 Derenne S, Amiot M, Barille S, Collette M, Robillard N, Berthaud P, Harousseau JL, Bataille R. "Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. " J Bone Miner Res 1999; 14: 2048-2056.

45 Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, Zangari M, Munshi NC, Anaissie E, Spoon D, Siegel D, Jagannath S, Vesole D, Epstein J, Shaughnessy J, Fassas A, Lim S, Roberson P, Crowley J. "Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. " Blood 2000; 95: 4008-4010.

46 Dhodapkar MV, Abe E, Theus A, Lacy M, Langford JK, Barlogie B. Sanderson RD. "Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. " Blood 1998a; 91: 2679-2688.

47 Dhodapkar MV, Singh J, Mehta J, Fassas A, Desikan KR, Perlman M, Munshi NC, Barlogie B. "Anti-myeloma activity of pamidronate in vivo. " Br J Haematol 1998b; 103: 530-532.

48 Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G. "Reduction in new metastases in breast cancer with adjuvant clodronate treatment. " N Engl J Med 1998; 339: 357-363.

49 Dirix LY, Vermeulen PB, Hubens G, Benoy I, Martin M, De Pooter C, Van Oosterom AT. "Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. " Ann Oncol 1996; 7: 843-848.

50 Dirix LY, Vermeulen PB, Pawinski A, Prove A, Benoy I, De Pooter C, Martin M, Van Oosterom AT. "Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. " Br J Cancer 1997; 76: 238-423.


105

51 Durie BGM, Salmon SE. "A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. " Cancer 1975; 36: 842-854.

52 Durie BGM. "Staging and kinetics of multiple myeloma. " Semin Oncol 1986; 13: 300-309.

53 Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J. "Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. " J Bone Mineral Res 1993; 8: 127-132.

54 Ezekowitz RA, Mulliken JB, Folkman J. "Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. " New Engl J Med 1992; 326: 1456-1463.

55 Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF. "Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. " J Exp Med 1994; 180: 341-346.

56 Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M, Hossfeld DK. "Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. " Blood 1997; 89: 1870-1875.

57 Fleisch H. "Bisphosphonates: Mechanisms of action. " Endocrine Rev 1998; 19: 80-100.

58 Folkman J, Klagsbrun M. "Vascular physiology. A family of angiogenic peptides. " Nature 1987; 329: 671-672.

59 Folkman J, Shing Y. "Angiogenesis. " J Biol Chem 1992; 267: 10931-10934.

60 Folkman J. "Angiogenesis in cancer, vascular, rheumatoid and other disease. " Nature Med 1995; 1: 27-31.

61 Folkman J. "New perspectives in clinical oncology from angiogenesis research. " Eur J Cancer 1996; 14: 2534-2539.

62 Fonseca R, Trendle MC, Leong T, Kyle RA, Oken MM, Kay NE, Van Ness B, Greipp PR. "Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. " Br J Haematol 2000; 109: 24-29.

63 Foss HD, Araujo I, Demel G, Klotzbach H, Hummel M, Stein H. "Expression of vascular endothelial growth factor in lymphomas and Castleman‘s disease. " J Pathol 1997; 183: 44-50.


106

64 Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L. "The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. " Nature 1994; 368: 237-239.

65 Gallego GM, Acenero MJ, Sanz Ortega J, Aljama A. "Vascular enumeration as a prognosticator for colorectal carcinoma. " Eur J Cancer 2000; 36: 55-60.

66 Gasparini G, Weidner N, Bevilacqua P, Maluta S, Dalla Palma P, Caffo O, Barbareschi M, Boracchi P, Marubini E, Pozza F. "Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. " J Clin Oncol 1994; 12: 454-466.

67 Gilbert C, Meisenberg B, Vredenburgh J, Ross M, Hussein A, Perfect J, Peters WP. "Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. " J Clin Oncol 1994; 12: 1005-1011.

68 Girasole G, Passeri G, Jilka RL, Manolagas SC. "Interleukin-11: a new cytokine critical for osteoclast development. " Journal of Clinical Investigation 1994; 93: 1516-1524.

69 Graham CH, Rivers J, Kerbel RS, Stankiewiscz KS, White WL. "Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas. " Am J Pathol 1994; 145: 510-514.

70 Grant MB, Caballero S, Millard WJ. "Inhibition of IGF-I and bFGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. " Regulatory Peptides 1993; 48: 267-278.

71 Gratwohl A, Passweg J, Baldomero H, Hermans J for the European Group for Blood and Marrow Transplantation. "Blood and marrow transplantation activity in Europe 1997. " Bone Marrow Transplant 1999; 24: 231-245.

72 Hanahan D, Folkman J. "Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. " Cell 1996; 86: 353-364.

73 Herwaldt LA, Hollis RJ, Boyken LD, Pfaller MA. "Molecular epidemiology of coagulase-negative staphylococci isolated from immunocompromised patients. " Infect Control Hosp Epidemiol 1992; 13: 86-92.

74 Hjertner O, Torgersen ML, Seidel C, Hjorth-Hansen H, Waage A, Borset M, Sundan A. "Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoclasts: "


107

"A possible role for HGF in myeloma associated osteolytic bone disease. " Blood 1999; 94: 3383-3388.

75 Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rodjer S, Westin J. "Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - a randomized study. " Eur J Haematol 1993; 50: 95-102.

76 Holmberg LA, Boeckh M, Hooper H, Leisenring W, Rowley S, Heimfeld S, Press O, Maloney DG, McSweeney P, Corey L, Maziarz RT, Appelbaum FR, Bensinger W. " Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. " Blood 1999; 94: 4029-4035.

77 Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL. "Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. " Lancet 1992; 340: 1120-1124.

78 Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, Pizzo P, Rolston KV, Shenep JL, Young LS. "1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. " Clin Infect Dis 1997; 25: 551-573.

79 Hussong JW, George MR, Shami PJ. "Evidence of increased angiogenesis in patients with acute myeloid leukemia. " Blood 2000; 95: 309-313.

80 Johnson MD, Kim HR, Chesler L, Tsao-Wu G, Bouck N, Polverini PJ. "Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. " J Cell Physiol 1994; 160: 194-202.

81 Karadag A, Oyajobi BO, Apperley JF, Russell RG, Croucher PI. "Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts. " Br J Haematol 2000; 108: 383-390.

82 Kawano MM, Huang N, Harada H, Harada Y, Sakai A, Tanaka H, Iwato K, Kuramoto A. "Identification of immature and mature myeloma cells in the bone marrow of human myelomas. " Blood 1993; 82: 564-557.

83 Ketterer N, Espinouse D, Chomarat M, Dumontet C, Moullet I, Rieux C, Neidhardt-Berard EM, Bouafia F, Coiffier B, Salles G. "Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. " Am J Med 1999; 106: 191-197.


108

84 Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. " Nature 1993; 362: 841-844.

85 Kini AR, Kay NE, Peterson LC. "Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. " Leukemia 2000; 14: 1414-1418.

86 Kolbe K, Domkin D, Derigs HG, Bhakdi S, Huber C, Aulitzky WE. "Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. " Bone Marrow Transplant 1997; 19: 143-147.

87 Königsberg R, Zojer N, Ackermann J, Kromer E, Kittler H, Fritz E, Kaufmann H, Nosslinger T, Riedl L, Gisslinger H, Jager U, Simonitsch I, Heinz R, Ludwig H, Huber H, Drach J. "Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. " J Clin Oncol 2000; 18: 804-812.

88 Krempien B. "Experimental findings on osteoprotective potential of bisphosphonates against bone metastases and tumor-induced osteopathy: A pleading for an early and preventive administration " in: Orr F and Singh G (eds.): Bone Metastasis - Mechanisms and pathophysiology ". " Springer, Heidelberg 1996.

89 Kunzmann V, Bauer E, Feurle J, Tony FW, Wilhelm M. "Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. " Blood 2000; 96: 384-392.

90 Kyle RA. "Multiple myeloma: review of 869 cases. " Mayo Clin Proc 1975; 50: 29-40.

91 Kyle RA. "Monoclonal gammopathy of undetermined significance (MGUS). " Baillière‘s Clin Haematol 1995; 8: 761-781.

92 Kyle RA, Gertz MA, Greipp PR, et al. "A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. " N Engl J Med 1997; 336: 1202-1207.

93 Laakso M, Lahtinen R, Virkkunen P, Elomaa I. "Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. " Br J Haematol 1994; 87: 725-729.

94 Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. "Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. " Lancet 1992; 340: 1049-1052.


109

95 Leibovich SJ, Polverini PJ, Fong TW, Harlow LA, Koch AE. "Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism. " Proc Natl Acad Sci USA 1994; 91: 4190-4194.

96 Link H, Maschmeyer G, Meyer P, Hiddemann W, Stille W, Helmerking M, Adam D for the Study Group of the Paul Ehrlich Society for Chemotherapy. "Interventional antimicrobial therapy in febrile neutropenic patients. " Ann Hematol 1994; 69: 231-243.

97 Liotta LA, Steeg PS, Stetler-Stevenson WG. "Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. " Cell 1991; 64: 327-336.

98 McCloskey EV, MacLennan IC, Drayson MT, Chapman C, Dunn J, Kanis JA. "A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. " Br J Haematol 1998; 100: 317-325.

99 Menzel T, Rahman Z, Calleja E, White K, Wilson EL, Wieder R, Gabrilove J. "Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. " Blood 1996; 87: 1056-1063.

100 Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. "Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. " Nature 1994; 367: 576-579.

101 Miyamoto T, Gondo H, Miyoshi Y, Shigematsu H, Minematsu T, Takenaka K, Tanimoto K, Horiuchi T, Asano Y, Inaba S, Minamishima Y, Niho Y. "Early viral complications following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. " Br J Haematol 1998; 100: 348-350.

102 Molica S, Vitelli G, Levato D, Gangolfo GM, Liso V. "Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukemia. " Br J Haematol 1999; 107: 605-610.

103 Montesano R. "Regulation of angiogenesis in vitro. " Eur J Clin Invest 1992; 22: 504-515.

104 Mossad SB, Longworth DL, Goormastic M, Serkey JM, Keys TF, Bolwell BJ. "Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. " Bone Marrow Transplant 1996; 18: 265-271.

105 Munshi N, Wilson CS, Penn J, Epstein J, Singhal S, Hough A, Sanderson R, Desikan R, Siegel D, Mehta J, Barlogie B. "Angiogenesis in newly diagnosed multiple myeloma: Poor prognosis with increased microvessel density in bone marrow biopsies. " Blood 1998; 92 (Suppl 1): 98a.


110

106 Munshi N, Desikan R, Zangari M, Badros A, Chodimella U, Toor A, Cromer J, Terry J, Anaissie E, Barlogie B. "Chemoangiotherapy with DT-PACE for previously treated multiple myeloma. " Blood 1999; 94 (Suppl 1): 123a.

107 Nakagawa M, Kaneda T, Arakawa T, Morita S, Sato T, Yomada T, Hanada K, Kumegawa M, Hakeda Y. "Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. " FEBS Lett 2000; 473: 161-164.

108 Niida S, Kaku M, Amano H, Yoshida H, Kataoka H, Nishikawa S, Tanne K, Maeda N, Nishikawa S, Kodama H. "Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. " J Exp Med 1999; 190: 293-298.

109 Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. "Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. " J Natl Cancer Inst 1994; 86: 356-361.

110 O‘Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. "Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. " Cell 1994; 79: 315-328.

111 Offidani M, Corvatta L, Olivieri A, Rupoli S, Frayfer J, Mele A, Manso E, Montanari M, Centurioni R, Leoni P. "Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF. " Bone Marrow Transplant 1999; 24: 1079-1087.

112 Oliver SJ, Banquerigo ML, Brahn E. "Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. " Cell Immunol 1994; 157: 291-299.

113 Ong F, Hermans J, Noordijk EM, Kluin-Nelemans JC. "Is the Durie and Salmon diagnostic classification system for plasma cell dyscrasias still the best choice? " Ann Hematol 1995; 70: 19-24.

114 Orfao A, Garcia-Sanz R, Lopez-Berges MC, Vidriales MB, Gonzales M, Caballero MD, San Miguel JF. "A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. " Cytometry 1994; 17: 332-339.


111

115 Padró T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, Buchner T, Berdel WE, Mesters RM. "Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. " Blood 2000; 95: 2637-2644.

116 Pecherstorfer M, Seibel MJ, Woitge HW. Horn E. Schuster J. Neuda J. Sagaster P. Kohn H. Bayer P. Thiebaud D. Ludwig H. "Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. " Blood 1997; 90: 3743-3750.

117 Perez-Atayde A, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. "Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. " Am J Pathol 1997; 150: 815-821.

118 Peterson DE. "Research advances in oral mucositis. " Curr Opin Oncol 1999; 11: 261-266.

119 Plate KH, Breier G, Millauer B, Ullrich A, Risau W. "Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. " Cancer Research 1993; 53: 5822-5827.

120 Pluijm G, Lowik C, Papapoulos S. "Tumour progression and angiogenesis in bone metastasis from breast cancer: new approaches to an old problem. " Cancer Treat Rev 2000; 26: 11-27.

121 Possinger K, Flath B, Akrivakis K. "Bisphosphonate im Behandlungskonzept des metastasierten Mammakarzinoms. " Geburtsh Frauenheilk 1996; 56: M91-M94.

122 Pruneri G, Bertolini F, Soligo D, Carboni N, Ferrucci PF, Buffa R, Lambertenghi-Deliliers G, Pezzella F. "Angiogenesis in myelodysplastic syndromes. " Br J Cancer 1999; 81: 1398-1401.

123 Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Lust JA, Greipp PR, Therneau TM, Kyle RA, Litzow MR, Gertz MA. "Autologous stem cell transplantation for relapsed and primary refractory myeloma. " Bone Marrow Transplant 1999a; 23: 1267-1272.

124 Rajkumar SV, Fonseca R, Witzig TE, Gertz MA, Greipp PR. "Bone marrow angiogenesis in complete responders after stem cell transplantation for multiple myeloma. " Leukemia 1999b; 13: 469-472.

125 Rapoport AP, Miller-Watelet LF, Linder T et al. "Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. " J Clin Oncol 1999; 17: 2446-2453.


112

126 Rastinejad F, Polverini PJ, Bouck NP. "Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. " Cell 1989; 56: 345-355.

127 Rawstron AC, Owen RG, Davies FE, Johnson RJ, Jones RA, Richards SJ, Evans PA, Child JA, Smith GM, Jack AS, Morgan GJ. "Circulating plasma cells in multiple myeloma: characterisation and correlation with stage disease. " Br J Haematol 1997; 97: 46-55.

128 Ribatti D, Vacca A, Nico B, Fanelli M, Roncalli L, Dammaco F. "Angiogenesis spectrum in the stroma of B-cell non-Hodgkin‘s lymphomas. An immunohistochemical and ultrastructural study. " Eur J Haematol 1996; 56: 45-53.

129 Risteli L, Risteli J. "Biochemical markers of bone metabolism. " Annals of Medicine 1993; 25: 385-393.

130 Ruescher TJ, Sodeifi A, Scrivani SJ et al. "The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. " Cancer 1998; 82: 2275-2281.

131 Saarto T, Blomqvist C, Virkkunen P, Elomaa I. "No reduction of bone metastases with adjuvant clodronate treatment in node-positive breast cancer patients. " Proc Am Soc Clin Oncol 1999; 18: 128a.

132 Sakuda H, Nakashima Y, Kuriyama S, Sueishi K. "Media conditioned by smooth muscle cells cultured in a variety of hypoxic environments stimulates in vitro angiogenesis. A relationship to transforming growth factor-beta1. " Am J Pathol 1992; 141: 1507-1516.

133 Salazar R, Solá C, Maroto P, Tabernero JM, Brunet J, Verger G, Valenti V, Cancelas JA, Ojeda B, Mendoza L, Rodriguez M, Montesinos J, López-López JJ. "Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. " Bone Marrow Transplant 1999; 21: 27-33.

134 Salven P, Manpaa H, Orpana A, Alitalo K, Joensuu H. "Serum vascular endothelial growth factor is often elevated in disseminated cancer. " Clin Cancer Res 1997a; 3: 647-651.

135 Salven P, Teerenhovi L, Joensuu H. "High pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin‘s lymphoma. " Blood 1997b; 90: 3167-3172.


113

136 Salven P, Ruotsalainen T, Mattson K, Joensuu H. "High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. " Int J Cancer 1998; 79: 144-146.

137 San Miguel JF, Garcia-Sanz R, Gonzalez M, Moro MJ, Hernandez JM, Ortega F, Borrego D, Carnero M, Casanova F, Jimenez R, et al. "A new staging system for multiple myeloma based on the number of S-phase plasma cells. " Blood 1995a; 85: 448-455.

138 San-Miguel JF, Garcia-Sanz R, Gonzalez M, Orfao A. "DNA cell content studies in multiple myeloma. " Leuk Lymphoma 1995b; 18: 179-184.

139 Schaar CG, Kaiser U, Snijder S, Ong F, Hermans J, Franck PFH, Kluin-Nelemans JC. "Serum interleukin-6 has no discriminatory role in paraproteinaemia nor a prognostic role in multiple myeloma. " Br J Haematol 1999; 107: 132-138.

140 Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Demuynck HM, Link H, Zander A, Barge A. "Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. " Lancet 1996; 347: 353-357.

141 Schneider U, Van Lessen A, Huhn D, Serke S. "Two subsets of peripheral blood plasma cells defined by differential expression of CD 45 antigen. " Br J Haematol 1997; 97: 56-64.

142 Schott RJ, Morrow LA. "Growth factors and angiogenesis. " Cardiovasc Res 1993; 27: 1155-1163.

143 Schweigerer L, Neufield G, Friedman J, Abraham JA, Fiddes JC, Gospodarowicz D. "Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. " Nature 1987; 325: 257-259.

144 Seidel C, Borset M, Turesson I, Abeldgaard N, Sundan A, Waage A. "Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. " Blood 1998; 91: 806-812.

145 Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, Abildgaard N, Waage A, Borset M. "Serum syndecan-1: a new independent prognostic marker in multiple myeloma. " Blood 2000; 95: 388-392.

146 Seong C, Delasalle K, Hayes K, Weber D, Dimopoulos M, Swantkowski J, Huh Y, Glassman A, Champlin R, Alexanian R. "Prognostic value of cytogenetics in multiple myeloma. " Br J Haematol 1998; 101: 189-194.


114

147 Seropian S, Nadkarni R, Jillella AP, Salloum E, Burtness B, Hu GL, Zelterman D, Cooper DL. "Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. " Bone Marrow Transplant 1999; 23: 599-605.

148 Sezer O, Bauhuis C, Metzner B, Wattad M, Fuss H, Eucker J, Heit W, Schultze W, Illiger HJ, Possinger K. "Multivariate analysis of factors influencing the rate of documented infections in 500 cycles high-dose chemotherapy with autologous peripheral stem cell transplantation. Jahrestagung der Deutschen Gesellschaft für Hämatologie und Onkologie 1999. " Onkologie 1999a; 25 (Suppl 1): 134.

149 Sezer O, Gatz F, Peh A, Schmid P, Mergenthaler HG, Possinger K. "Liposomal daunorubicin in multiple myeloma: Results of a phase I study of a modified VAD regimen using short-term infusion. 7th International Multiple Myeloma Workshop, " Stockholm , 1999b: Abstract 68.

150 Sezer O, Schmid P, Mergenthaler H-G, Beinert T, Possinger K. "Use of bisphosphonates in therapy and prophylaxis of cancer-induced bone diseases. " Onkologie 1999c; 22: 400-404.

151 Sezer O, Schmid P, Schweigert M, Heider U, Eucker J, Harder H, Sinha P, Radtke H, Possinger K. "Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support. " Bone Marrow Transplant 1999d; 23: 967-969.

152 Sezer O, Eucker J, Bauhuis C, Schweigert M, Lüftner D, Kalus U, Späth-Schwalbe E, Arnold R and Possinger K. "Patients with malignant lymphoma experience a higher rate of documented infections than patients with breast cancer after high-dose chemotherapy with autologous peripheral stem cell transplantation. " Ann Hematol 2000a; 79: 627-630.

153 Sezer O, Eucker J, Fuss H, Bauhuis C, Kobert U, Heinzel W, Späth-Schwalbe E, Arnold R, Possinger K, Schultze W. "Infectious complications during high dose therapy with autologous peripheral blood stem cell transplantation. " In: High Dose Therapy and Transplantation of Haematopoietic Stem Cells. Blackwell , 2000b: 90-93.

154 Sezer O, Eucker J, Heider U, Schweigert M, Schmid P, Possinger K. "Therapeutic strategies in primary AL-amyloidosis. " In: High Dose Therapy and Transplantation of Haematopoietic Stem Cells. Blackwell , 2000c: 21-26.


115

155 Sezer O, Eucker J, Jakob C, Possinger K. "Diagnosis and treatment of AL amyloidosis. " Clin Nephrol 2000d; 53: 417-423.

156 Sezer O, Eucker J, Metzner B, Wattad M, Fuss H, Bauhuis C, Heit W, Schultze W, Illiger HJ, Possinger K. "Mucositis is associated with increased rate of documented infections and treatment-related mortality after high-dose therapy with autologous peripheral stem-cell transplantation. American Society of Clinical Oncology, 36th Annual Meeting, 2000. " Proc Am Soc Clin Oncol 2000e; 19: 56a.

157 Sezer O, Eucker J, Schmid P, Possinger K. "New therapeutic approaches in primary systemic AL amyloidosis. " Ann Hematol 2000f; 79: 1-6.

158 Sezer O, Jakob C, Eucker J, Niemöller K, Schweigert M, Possinger K. "Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. American Society of Hematology, 42nd Annual Meeting, San Fransisco, 2000. " Blood 2000g; 96 (Suppl): 366a.

159 Sezer O, Niemöller K, Eucker J, Jakob C, Kaufmann O, Zavrski I, Dietel M, Possinger K. "Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. " Ann Haematol 2000h; 79: 574-577.

160 Sezer O, Niemöller K, Jakob C, Langelotz C, Eucker J, Possinger K. "Novel approaches to the treatment of primary amyloidosis. " Exp Opin Invest Drugs 2000i; 9: 2343-2350.

161 Sezer O, Niemöller K, Schweigert M, Kaufmann O, Jakob C, Zavrski I, Eucker J, Possinger K. "Bone marrow microvessel density is a prognostic factor for survival in multiple myeloma and a significant decrease in microvessel density occurs in patients who achieve a remission after chemotherapy. American Society of Hematology, 42nd Annual Meeting, San Fransisco, 2000. " Blood 2000j; 96 (Suppl): 363a.

162 Sezer O, Possinger K, Metzner B, Illiger H-J, Wattad M, Heit W, Fuss H, Schultze W. "Optimal CD 34+ cell dose in autologous peripheral stem-cell transplantation. " J Clin Oncol 2000k; 18: 3319-3320.

163 Sezer O, Weis J, Watson M, Hjermstad MJ, Kopp M, Morris P and Velikova G on behalf of EORTC Quality of Life Study Group. "Development of an EORTC module for quality-of-life assessment of cancer patients receiving high-dose chemotherapy with stem cell transplantation. Jahrestagung der Deutschen Gesellschaft für Hämatologie und Onkologie, Graz, 2000. " Onkologie 2000l; 23 (Suppl 7): 190.


116

164 Sezer O, Jakob C, Eucker J, Niemöller K, Gatz F, Wernecke KD, Possinger K. "Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. " Eur J Haematol 2001a (in press).

165 Sezer O, Niemöller K, Kaufmann O, Eucker J, Jakob C, Schweigert M, Possinger K. "Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy. " Eur J Haematol 2001b (in press).

166 Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI. "Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. " Br J Haematol 1997; 98: 665-672.

167 Shweiki D, Itin A, Soffer D, Keshet E. "Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. " Nature 1992; 359: 843-845.

168 Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J, Barlogie B. "Antitumor activity of thalidomide in refractory multiple myeloma. " N Engl J Med 1999; 341: 1565-1571.

169 Sjak-Shie NN, Sultur GG, Said JW, Schrage M, Vescio RA, Berenson JR. "Vascular endothelial growth factor and angiogenesis in multiple myeloma. " Blood 1999; 94(Suppl 1): 305b.

170 Sone T, Miyake M, Takeda N, Fukunaga M. "Urinary excretion of type I collagen crosslinked N-telopeptides in healthy Japanese adults: age- and sex-related changes and reference limits. " Bone 1995; 17: 335-339.

171 Stead M, Brown J, Velikova G, Kaasa S, Wisloff F, Child A, Hippe E, Hjorth M, Sezer O and Selby P for the EORTC Study Group on Quality of Life. "Development of an EORTC questionnaire module to be used in quality of life assessment for patients with multiple myeloma. " Brit J Haematol 1999; 104: 605-611.

172 Stoker M, Gherardi E, Perryman M, Gray J. "Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. " Nature 1987; 327: 239-242.

173 Taniguchi T, Toi M, Inada K, Imazawa T, Yamamoto Y, Tominaga T. "Serum concentrations of hepatocyte growth factor in breast cancer patients. " Clin Cancer Res 1995; 1: 1031-1034.

174 Teicher BA, Holden SA, Ara G, Northey D. "Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents. " Anticancer Res 1993; 13: 2101-2106.


117

175 Thornton CO, Ballester O, Greenfield GB. "Progression of bone disease in multiple myeloma patients treated with high dose therapy and autologous stem cell transplantation. " Blood 1996; 88 (Suppl.); 481a.

176 Tricot G. "New insights into role of microenvironment in multiple myeloma. " Lancet 2000; 355: 248-250.

177 Tsujimoto T, Lisukov IA, Huang N, Mahmoud MS, Kawano MM. "Plasma cells induce apoptosis of pre-B cells by interacting with bone marrow stromal cells. " Blood 1996; 87: 3375-3383.

178 Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, Dammacco F. "Bone marrow angiogenesis and progression in multiple myeloma. " Br J Haematol 1994; 87: 503-508.

179 Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, Albini A, Bussolino F, Dammaco F. "Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. " Blood 1999a; 93: 3064-3073.

180 Vacca A, Ribatti D, Ruco L, Giacchetta F, Nico B, Quondamatteo F, Ria R, Iurlaro M, Dammacco F. "Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. " Br J Cancer 1999b; 79: 965-970.

181 Van Zaanen HCT, Vet RJWM, De Jong CM, Von dem Borne AEGK, Van Oers MHJ. "A simple and sensitive method for determining plasma cell isotype and monoclonality in bone marrow using flowcytometry. " Br J Haematol 1995; 91: 55-59.

182 Vermeulen PB, Salven P, Benoy I, Gasparini G, Dirix LY. "Blood platelets and serum VEGF in cancer patients. " Br J Cancer 1999; 79: 370-373.

183 Wakui S, Furusato M, Itoh T, Sasaki H, Akiyama A, Kinoshita I, Asano K, Tokuda T, Aizawa S, Ushigome S. "Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study. " J Pathol 1992; 168: 257-262.

184 Weber DM, Gavino M, Delasalle K, Rankin K, Giralt S, Alexanian R. "Thalidomide alone or with dexamethasone for multiple myeloma. " Blood 1999; 94 (Suppl 1): 604a.

185 Weidner N, Semple JP, Welch WR, Folkman J. "Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. " New Engl J Med 1991; 324: 1-8.

186 Weinstat-Saslow D, Steeg PS. "Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. " FASEB J 1994; 8: 401-407.


118

187 White CW, Wolf SJ, Korones DN, Sondheimer HM, Tosi MF, Yu A. "Treatment of childhood angiomatous diseases with recombinant interferon alfa-2a. " J Pediatr 1991; 118: 59-66.

188 Wijdenes J, Vooijs WC, Clement C, Post J, Morard F, Vita N, Laurent P, Sun RX, Klein B, Dore JM. "A plasmocyte selective monoclonal antibody (B-B4) recognise syndecan-1. " Br J Haematol 1996; 94: 318-323.

189 Witzig TE, Kimlinger TK, Ahmann GJ, Katzmann JA, Greipp PR. "Detection of myeloma cells in the peripheral blood by flow cytometry. " Cytometry 1996; 26: 113-120.

190 Witzig T, Kimlinger T, Stenson M, Thereneau T. "Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. " Leuk Lymphoma 1998; 31: 167-175.

191 Woitge HW, Pecherstorfer M, Li Y, Keck AV, Horn E, Ziegler R, Seibel MJ. "Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. " J Bone Mineral Res 1999; 14: 792-801.


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.

DiML DTD Version 2.0
Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML - Version erstellt am:
Mon Sep 30 13:32:44 2002